Burris H 3rd et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as firstline treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22(9):1621-9. Abstract

Burstein HJ et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21(1):46-53. Abstract

Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract

Buzdar AU et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc ASCO 2004;Abstract 520.

Geyer CE Jr et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, nodepositive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res Treat 2003;Abstract 23.

Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract

Montemurro F et al. A phase II study of threeweekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004;66(1):38-45. Abstract

Pegram MD et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96(10):759-69. Abstract

Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the north central cancer treatment group n9831 intergroup adjuvant trial. J Clin Oncol 2004;22(18):3700-4. Abstract

Robert NJ et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Proc ASCO 2004;Abstract 573.

Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. Abstract

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Slamon D et al. Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC). Proc ASCO 2004;Abstract 642.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Tedesco KL et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization- positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004;22(6):1071-7. Abstract

Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract

Valero V et al. Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. Proc ASCO 2004;Abstract 572.